Investigation of preventive effect with neurotropin for neuropathy due to paclitaxel

Investigation of preventive effect with neurotropin for neuropathy due to paclitaxel - Investigation of preventive effect with neurotropin for neuropathy due to paclitaxel

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012211

Enrollment

Registered

2014-01-01

Start date

2014-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The patient of gynecologic cancer treated with paclitaxel

Interventions

neurotropin

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: The patients necessary for chemotherapy with paclitaxel doe to gynecologic cancer (vertical cancer, corpus cancer, ovarian cancer, tubal cancer and peritoneal cancer)

Exclusion criteria

Exclusion criteria: The patient with neuropathy due to other reason such as diabetes merits THe patient with neuropathy due to progressive original disease

Design outcomes

Primary

Measure	Time frame
Level of sensory neuropathy	—

Secondary

Measure	Time frame
level of motor neuropathy	—

Countries

Japan

Contacts

Public ContactMasato Nishimura

The University of Tokushima Department of Obsterics and Gynecology

nishimura.masato@tokushima-u.ac.jp088-633-7177

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026